TA的每日心情 | 2022-2-14 15:59 |
---|
|
一项研究显示埃索美拉唑对氯吡格雷的抗血小板作用亦无明显影响。
1: Thromb Haemost. 2009 Apr;101(4):714-9.
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M, Schömig A,
Kastrati A, von Beckerath N.
Deutsches Herzzentrum and 1. Medizinische Klinik rechts der Isar, Lazarettstrasse
36, 80636 München, Germany. E-mail: dirk@sibbing.net.
Patients receiving dual antiplatelet treatment with aspirin and clopidogrel are
commonly treated with proton pump inhibitors (PPIs). Attenuating effects on
platelet response to clopidogrel have been reported solely for the PPI
omeprazole. PPIs differ in their metabolisation properties as well as their
potential for drug-drug interactions. The aim of this study was to investigate
the impact of different PPIs (pantoprazole, omeprazole, esomeprazole) on platelet
response to clopidogrel in patients with previous coronary stent placement under
chronic clopidogrel treatment. In a cross-sectional observational study,
consecutive patients under clopidogrel maintenance treatment (n = 1,000)
scheduled for a control coronary angiography were enrolled. Adenosine diphosphate
(ADP)-induced platelet aggregation (in AU*min) was measured with multiple
electrode platelet aggregometry (MEA). From the entire study population, 268
(26.8%) patients were under PPI treatment at the time point of platelet function
testing (pantoprazole, n = 162; omeprazole, n = 64; esomeprazole, n = 42).
Platelet aggregation (median [interquartile range]) was significantly higher in
patients with omeprazole treatment (295.5 [193.5-571.2] AU*min) compared to
patients without PPI treatment (220.0 [143.8-388.8] AU*min; p = 0.001). Platelet
aggregation was similar in patients with pantoprazole (226.0 [150.0-401.5]
AU*min) or esomeprazole (209.0 [134.8-384.8] AU*min) treatment compared to
patients without PPI treatment (p = 0.69 and p = 0.88, respectively). Attenuating
effects of concomitant PPI treatment on platelet response to clopidogrel were
restricted to the use of omeprazole. No attenuating effects on platelet response
to clopidogrel were observed for pantoprazole or esomeprazole. Specifically
designed and randomized clinical studies are needed to define the impact of
concomitant PPI treatment on adverse events after percutaneous coronary
intervention. |
|